Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 2;9:11286. doi: 10.1038/s41598-019-47802-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Sequential therapy of anti-PD-1 and anti-CTLA-4. (A) From top to bottom: Tumor response to sequential therapy with dosing as listed in phase II CheckMate 064 trial (NCT01783938) with regimens shown in bottom two figures. Following response (top), effector T cell density in the tumor (second from the top), mAPC density in the lymph nodes (third from the top) and finally, the PK of anti-PD-1 first regimen and lastly, anti-CTLA-4 first regimen. (B) Anti-PD-1 therapy first: Comparison of variability in responses (top), waterfall plots of responders in virtual trial (second from top), Bar graph comparison parameters varied in model for each responder type (third from top), and boxplots of Max effector T cell density in the tumor and average mAPC density in the lymph nodes (bottom) for each responder category: virtual non-responders (NR), stable disease (SD) and partial or complete responders (CR/PR). (C) Same as (B), except for anti-CTLA-4 therapy administered first.